General population-based cohort
Alzheimer's disease, Other NDs not listed, Vascular dementia
ASPREE is a double-blind, randomized, placebo-controlled primary prevention trial designed to assess whether daily active treatment of 100 mg enteric-coated aspirin will extend the duration of disability-free life in healthy participants aged 70 years and above except for Hispanic and African American minority groups in the U.S. where the minimum age of entry is 65 years.
The primary objective is to determine whether low-dose aspirin prolongs life, or life free of dementia, or life free of significant, persistent physical disability in the healthy elderly. Secondary objectives relate to the effects of low-dose aspirin on the key outcome areas of death, cardiovascular disease, dementia and cognitive decline, cancer, physical disability, depression and major bleeding episodes. Variables were collected annually through visits and for the purposes of retention telephone calls were scheduled at set points through the 7 years.
ASPREE Project Manager, Brenda Kirpach
Berman Center for Outcomes & Clinical Research
701 Park Ave, Suite PPC4.440
Minneapolis, MN 55415
ASPREE National Co-ordinating and Clinical Trial Centre,
Ground Floor, Burnet Building
89 Commercial Road, Melbourne 3004